Dermira eyes $80M IPO; Merck: Patients are open to sharing their genomes;

@FierceBiotech: FierceBiotech's 2014 Fierce 15. Congrats to those who made the list! | Follow @FierceBiotech

@JohnCFierce: Always fun to watch the web traffic explode when we blast the Fierce 15. | Follow @JohnCFierce

@DamianFierce: Merck KGaA gets around to that big deal it's been talking up: $SIAL for $17B. More | Follow @DamianFierce

> Dermira is looking to pull off an $80 million IPO, seeking cash to bankroll its pipeline of treatments for psoriasis, acne and excessive sweating. News

> San Diego's Lpath ($LPTN) signed a deal to raise $12.5 million to advance its platform of lipid-targeted antibodies. More

> A survey conducted by Merck ($MRK) suggests that patients are willing to hand over their genomic information--at a price--to help drugmakers craft new therapies. Story

Medical Device News

@FierceMedDev: Zimmer partners with MiMedx to sell bioimplants to promote healing. Article | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. Story | Follow @MichaelGFierce

@VarunSaxena2: Court ruling against FDA should enable more combination products to be classified as devices. Article | Follow @VarunSaxena2

@EmilyWFierce: British startup launches crowdfunding effort for 3-D printed orthotic devices. More | Follow @EmilyWFierce

> University of Louisville working on 'bioficial heart' using 3-D printing. Story

> Physicians defend power morcellator devices amid industry fallout. Article

Pharma News

@FiercePharma: Eylea gets yet another approval, this one in Japan. More | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. Article | Follow @EricPFierce

@CarlyHFierce:  Inversion pushback won't scare Horizon Pharma out of Ireland move. Story | Follow @CarlyHFierce

> Auxilium says Endo offer not enough to break off with QLT. News

> Merck KGaA declares $17B Sigma purchase 'quantum leap' as drug biz struggles. Article

> Eylea gets yet another approval, this one in Japan. More

CRO News

> Packaging outfit PCI buys trial supplier Biotec. News

> Survey says: Big CROs are only getting bigger. Report

> CRO FlowMetric gets into diagnostics with new spinout. Story

> TransCelerate dishes on risk-based monitoring. Item

> Covance borrows Fresenius' data to improve kidney treatments. Article

Biotech IT News

> Vivametrica makes pitch for mHealth data aggregation and analysis market. Report

> Stanford and Duke to trial Apple's HealthKit for remote data collection. More

> Merck survey finds patients willing to share NGS data with pharma companies. Story

> BBK bags $3M to expand its eClinical suite. Item

> AstraZeneca opens Indian IT center as 13-year outsourcing experiment nears end. Article

Animal Health News

> Work on the National Bio and Agro-Defense Facility continues. More

> EU gives nod to Merck's poultry vaccine to fight infectious bronchitis. Report

> Phibro reports strong sales in animal growth and nutrition sectors. Article

> Will Zoetis stand alone when Big Pharma's music stops? More

> Packaging outfit PCI buys trial supplier Biotec. Story

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.